Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.34 |
| ▸ | GIPR | P48546 | 8/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | GCG | P01275 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 2/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258262 | 0.95 | GCGR (0.34) | GCGRGIPRRORC | |
| SCHEMBL17501183 | 0.93 | CCRL2 (0.32) | RORCAURKARPS6KB1AURKBPDPK1 | |
| SCHEMBL19640542 | 0.92 | RORC (0.33) | RORCAURKARPS6KB1P2RX7 | |
| SCHEMBL19640638 | 0.91 | RORC (0.34) | RORCAURKARPS6KB1AURKBPDPK1 | |
| SCHEMBL19640653 | 0.90 | MKNK2 (0.34) | RORCAURKARPS6KB1 | |
| SCHEMBL19640668 | 0.89 | RORC (0.33) | RORCAURKARPS6KB1AURKBPDPK1 | |
| SCHEMBL24258274 | 0.88 | RORC (0.31) | GCGRRORC | |
| SCHEMBL17501303 | 0.87 | CCRL2 (0.32) | RORCAURKARPS6KB1AURKBPDPK1 | |
| SCHEMBL19650899 | 0.87 | CSF1R (0.34) | RORCAURKARPS6KB1AURKBPDPK1 | |
| SCHEMBL29400660 | 0.86 | RORC (0.31) | RORCP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20200392140-A1 | OPTIONALLY FUSED HETEROCYCLYL- SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2020-12-17 | — | — | US | disclosed |
| US-20200392140-A1 | OPTIONALLY FUSED HETEROCYCLYL- SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2020-12-17 | — | — | US | disclosed |
| US-10683293-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-16 | — | — | US | disclosed |
| US-10683293-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-16 | — | — | US | disclosed |
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-30 | — | — | US | disclosed |
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | PPARD, PPARG, RORC | GCGR 657/4885GIPR 1395/4885RORC 3/4885 |
| US-20200392140-A1 | OPTIONALLY FUSED HETEROCYCLYL- SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | GCGR 657/4885GIPR 1395/4885RORC 3/4885 |
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | GCGR 657/4885GIPR 1395/4885RORC 3/4885 |
| US-10683293-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | PPARD, PPARG, RORC | GCGR 657/4885GIPR 1395/4885RORC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.